IMMUNEXT, INC.

Biotech · Private

Antibody-drug conjugate (ADC) delivering glucocorticoid to immune cells with reduced systemic toxicity

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Total capital: $12.3M

Federal grants: $12.3M; 15 awards · 2015–2023; Rank in peer group#31 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 4; 25 pending · first 2019; Rank in peer group#85 of 514

Capital timeline

Latest events

Jun 2023Federal grantHealth and Human S · Phase II · Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases$112
May 2022Federal grantHealth and Human S · Phase II · Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases$975K
Jun 2021Federal grantHealth and Human S · Phase II · Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases$991K
Jul 2020Federal grantHealth and Human S · Phase II · Targeting leukocyte metabolism to treat human autoimmune disease$996K
Jul 2019Federal grantHealth and Human S · Phase II · Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$1M
Jun 2019Federal grantHealth and Human S · Phase II · Targeting leukocyte metabolism to treat human autoimmune disease$996K
Aug 2018Federal grantHealth and Human S · Phase II · Targeting leukocyte metabolism to treat human autoimmune disease$996K

Show 8 earlier federal awards

Jul 2018Federal grantHealth and Human S · Phase II · Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$992K
Feb 2018Federal grantHealth and Human S · Phase II · Targeting leukocyte metabolism to treat human autoimmune disease$300K
Aug 2017Federal grantHealth and Human S · Phase II · Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$992K
Apr 2017Federal grantHealth and Human S · Phase II · Safe and effective anti CD154 antibodies for therapeutic intervention$912K
Feb 2017Federal grantHealth and Human S · Phase II · Targeting the checkpoint regulator VISTA for treatment of inflammatory disease$300K
May 2016Federal grantHealth and Human S · Phase II · Safe and effective anti CD154 antibodies for therapeutic intervention$912K
Apr 2015Federal grantHealth and Human S · Phase II · Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease$954K
Feb 2015Federal grantHealth and Human S · Phase II · Safe and effective anti CD154 antibodies for therapeutic intervention$1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#31 · top 6%
Granted patents#85 · top 17%
Linked publications#44 · top 9%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 4 granted of 29

Jun 16, 2026GrantedANTI-CD154 Antibody Having Improved Binding, Functional And Safety Characteristics And Use In Human ImmunotherapyUSPTOUS 12,653,884
Apr 3, 2025PendingNOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOFUSPTOApplication 18271106
Oct 5, 2023PendingAnti-human Vista Antibodies And Use ThereofUSPTOApplication 17920445

Show all 29 patent records

ANTI-CD154 Antibody Having Improved Binding, Functional And Safety Characteristics And Use In Human ImmunotherapyJun 16, 2026 · US 12,653,884Granted
NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOFApr 3, 2025 · Application 18271106Pending
Anti-human Vista Antibodies And Use ThereofOct 5, 2023 · Application 17920445Pending
Methods Of Immunouppression Comprising Administering An ANTI-CD154 AntibodyMar 7, 2023 · US 11,596,689Granted
ANTI-CD154 Antibody Having Improved Binding, Functional And Safety CharacteristicsDec 29, 2020 · US 10,874,738Granted
Identification Of VSIG8 As The Putative Vista Receptor (v-r) And Use Thereof To Produce VISTA/VSIG8 Agonists And AntagonistsJun 25, 2020 · Application 16531968Pending
Identification Of VSIG8 As The Putative Vista Receptor (v-r) And Use Thereof To Produce VISTA/VSIG8 Agonists And AntagonistsAug 6, 2019 · US 10,370,455Granted
Anti-human Vista Antibodies And Use ThereofOct 26, 2017 · Application 15489192Pending
Anti-human Vista Antibodies And Use ThereofOct 26, 2017 · Application 15489209Pending
Anti-human Vista Antibodies And Use ThereofApplication 63251939Pending
Anti-human Vista Antibodies And Use ThereofApplication 63246941Pending
Anti-human Vista Antibodies And Use ThereofApplication 63188499Pending
Anti-human Vista Antibodies And Use ThereofApplication 63186447Pending
Anti-human Vista Antibodies And Use ThereofApplication 63178378Pending
Anti-human Vista Antibodies And Use ThereofApplication PCTUS2021028698Pending
Anti-vista Antibody Steroid Conjugates And Use ThereofApplication 63138958Pending
Anti-vista Antibody Steroid Conjugates And Use ThereofApplication 63134811Pending
Anti-human Vista Antibodies And Use ThereofApplication 63013887Pending
Anti-human Vista Antibodies And Use ThereofApplication 63013878Pending
ANTI-CD154 Antibody Having Improved Binding, Functional And Safety Characteristics And Use In Human ImmunotherapyApplication PCTUS2016042074Pending
Identification Of VSIG8 As The Putative Vista Receptor (v-r) And Use Thereof To Produce VISTA/VSIG8 Agonists And AntagonistsApplication PCTUS2015064146Pending
ANTI-VISTA ANTIBODY RNA OR NUCLEIC ACID CONJUGATES (ARCs or ANCs) AND THERAPEUTICS USESApplication 63506177Pending
Development Of Vista-centric Tumor Immunophenotyping For Identification Of Potential Biomarkers For Anti-vista TherapyApplication PCTUS2023067824Pending
Development Of Vista-centric Tumor Immunophenotyping For Identification Of Potential Biomarkers For Anti-vista TherapyApplication 63419511Pending
Development Of Vista-centric Tumor Immunophenotyping For Identification Of Potential Biomarkers For Anti-vista TherapyApplication 63415107Pending
NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOFApplication 63290100Pending
NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOFApplication 63284886Pending
NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOFApplication 63271554Pending
STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOFApplication 63271023Pending

Recent research by its founders

Characterization of Anti-Canine PD-1 Antibodies20260 cites
GPR17 as a Macrophage Sensor for Gram-Positive Peptidoglycan: Implications for Invasive Bacterial Infection20260 cites
GPR17 as an Innate Sensor for Bacterial Peptidoglycan: Implications for Necrotizing Fasciitis20260 cites

TARN BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
ADVANCED PROCESS COMBINATORICS, INC.Similar federal contract value in Biotech · null in contracts
Atara BiotherapeuticsSimilar federal contract value in Biotech · null in contracts
NOVORON BIOSCIENCE INCSimilar federal contract value in Biotech · null in contracts
ADAPTIN BIO, INC.Similar federal contract value in Biotech · null in contracts
Tolera Therapeutics IncSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.